Janel Corporation (JANL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 82 | 146 | 317 | 186 | 183 | 207 | 237 | - |
| Operating profit | $m | 6 | 7 | ||||||
| Net profit | $m | -2 | 5 | -2 | 1 | 1 | 5 | 6 | - |
| EPS reported | $ | 4.17 | 4.51 | ||||||
| Operating cashflow per share | $ | 36.30 | 22.18 | ||||||
| Capex per share | $ | 0.50 | 0.36 | ||||||
| FCF per share | $ | 35.80 | 21.81 | ||||||
| Free cash flow | $m | 42 | 45 | ||||||
| Net debt | $m | 3 | -0 | ||||||
| Book value equity | $m | 26 | 27 | ||||||
| Book value per share | $ | 21.41 | 22.38 | ||||||
| Number of shares | m | 1.21 | 1.22 | ||||||
| DPS (TTM paid) | $ | 0.84 | 1.36 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 8.64 | 13.52 | ||||||
| P/B LTM | x | 1.66 | 1.57 | ||||||
| P/S LTM | x | 0.21 | 0.18 | ||||||
| P/FCF LTM | x | 1.01 | 0.95 | ||||||
| EV/EBITDA LTM | x | 4.39 | 3.96 | ||||||
| EV/Sales LTM | x | 0.26 | 0.38 | ||||||
| Earnings Yield LTM | % | +11.57% | +7.40% | ||||||
| FCF Yield | % | +99.42% | +105.62% | ||||||
| Quality | |||||||||
| ROE | % | +20.98% | +19.22% | ||||||
| ROIC | % | +9.11% | +6.51% | ||||||
| Operating margin | % | +3.10% | +2.55% | ||||||
| Gross margin | % | +31.33% | +31.63% | ||||||
| FCF/Sales | % | +20.48% | +11.82% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +2216.7% | +2405.6% | ||||||
| Sales Growth YoY | % | +13.24% | +29.49% | ||||||
| Net Income Growth YoY | % | +882.58% | +971.51% | ||||||
| FCF Growth | % | +628.70% | +674.13% | ||||||
| Operating Profit Growth | % | +71.21% | +93.93% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +2.36% | 0.00% | ||||||
| Dividend Growth | % | +1100.8% | +1859.1% | ||||||
| Payout Ratio | % | +20.05% | +78.65% | ||||||
| FCF/Debt | x | 1.83 | 1.11 | ||||||
| Net Debt/EBITDA | x | 0.91 | 2.34 | ||||||
| EBIT/Net interest | x | 3.10 | 3.57 | ||||||
| Net debt/market cap | % | +34.68% | +50.47% | ||||||
| Net debt/Equity | x | 0.11 | -0.01 | ||||||
| Gross debt/equity | x | 0.90 | 1.50 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Headquartered in New York, NY, Janel Corporation was founded in 1974 and provides a range of services worldwide through its various subsidiaries. The firm adopted its current name in April 2015, previously known as Janel World Trade Ltd. Janel operates across three core business segments: Logistics, Manufacturing, and Life Sciences. The Logistics segment specializes in global cargo movement and supply chain management. This encompasses freight forwarding across air, ocean, and ground modalities, alongside customs brokerage, warehousing, distribution, and supplementary services such as customs filing, cargo insurance procurement, strategic logistics planning, product repackaging, and real-time shipment tracking. Within the Manufacturing division, the company develops and distributes mixing apparatus and equipment catering to diverse industries, including chemicals, inks, paints, construction, plastics, adhesives, cosmetics, food, and pharmaceuticals. Lastly, the Life Sciences segment is dedicated to the production and supply of monoclonal and polyclonal antibodies, diagnostic reagents, and other immunologic reagents crucial for biomedical research. This segment further supports academic and industrial research scientists through antibody manufacturing, and produces items for other life science enterprises on an original equipment manufacturer (OEM) basis.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Headquartered in New York, NY, Janel Corporation was founded in 1974 and provides a range of services worldwide through its various subsidiaries. The firm adopted its current name in April 2015, previously known as Janel World Trade Ltd. Janel operates across three core business segments: Logistics, Manufacturing, and Life Sciences. The Logistics segment specializes in global cargo movement and supply chain management. This encompasses freight forwarding across air, ocean, and ground modalities, alongside customs brokerage, warehousing, distribution, and supplementary services such as customs filing, cargo insurance procurement, strategic logistics planning, product repackaging, and real-time shipment tracking. Within the Manufacturing division, the company develops and distributes mixing apparatus and equipment catering to diverse industries, including chemicals, inks, paints, construction, plastics, adhesives, cosmetics, food, and pharmaceuticals. Lastly, the Life Sciences segment is dedicated to the production and supply of monoclonal and polyclonal antibodies, diagnostic reagents, and other immunologic reagents crucial for biomedical research. This segment further supports academic and industrial research scientists through antibody manufacturing, and produces items for other life science enterprises on an original equipment manufacturer (OEM) basis.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free